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Introduction
Hepatitis B virus (HBV) affects more than 2 billion peo-
ple worldwide and approximately 247 million chronic 
individuals are known to be chronic carriers (Caligiuri 
et al. 2016; WHO 2018). HBV can cause severe liver 
infections and cirrhosis may develop in 15–40% of indi-
viduals if they are not treated (Tang et al. 2018). There 
are several novel treatment strategies that have been 
used for the treatment of chronic hepatitis B infection 
in order to prevent the risk of developing liver failure, 
cirrhosis, and cancer (Lapiński et al. 2013). Interferon 
alpha (IFN-α) 2a- 2b, PEGylated interferon-α-2a 
(Pegasys), PEGylated interferon-α-2b (Pegintron), and 
nucleos(t)ide analogues (NAs) are worldwide used for 
fighting chronic hepatitis B (CHB) infection by sup-
pressing HBV replication (Ward et al. 2016). Lamivu-
dine (LAM), telbivudine (LdT), entecavir (ETV), adefo-
vir (ADV), and tenofovir (TDF) are antiviral agents that 
have been approved in Europe, America and many Asia-
Latin America countries for the treatment of chronic 
HBV, however, there is a big concern of long term use 
of these agents as they are associated with the develop-
ment of antiviral resistance mutations (Sun et al. 2016; 
Ozguler and Sayan 2016; Zhao et al. 2016; Ozguler and 
Sayan 2018). These mutations are associated with the 
amino acid substitutions in the reverse transcriptase 
(RT) domain and are classified as primary or secondary 
compensatory resistance mutations (Rugieri Pacheco 
et al. 2017). Mutations at the amino acid positions 
rt169, rt181, rt184, rt194, rt202, rt204, rt236, rt250 are 
classified as the primary resistance mutations which 
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A b s t r a c t
Mutations associated with the pol and the S gene can emerge as a consequence of the high replication capacity and proofreading deficien-
cies of hepatitis B virus during replication. The current study was constructed to evaluate primary, partial, compensatory and the escape 
mutations in chronic hepatitis B patients in Northern Cyprus. The samples of HBsAg positive treatment naïve 100 patients were involved 
in this study. HBV pol gene region was sequenced, amplified and HBV pol/S gene mutations were determined. The samples of thirty-two 
patients were excluded because of their low viral load (HBV < 1000 ıu/ml). Among the sequenced 68 samples, there was a partial mutation 
(1.5%) and 36.7% displayed a resistance profile to lamivudine, adevofir, and telbivudine. Immune response escape, vaccine escape, HBIg 
and diagnosis escape mutations were determined in 24%, 10%, 6%, and 4% samples of the patients, respectively. Additionally, there were 
six different combined mutations. These data underscored that there is no concern for primary mutations in Northern Cyprus, however, 
we have identified a compensatory mutation (rtV173M) that may have primary mutation characteristics by combining with other muta-
tion patterns. Additionally, HBsAg escape mutants demonstrated that detection of the S gene together with the pol gene mutations might 
be beneficial and important to monitor the surveillance of S variants.
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are associated with reducing the sensitivity to anti-
virals, whereas, the secondary compensatory resistance 
mutations occur at the amino acid positions rt80, rt173, 
rt180 and generally restore the replication capability of 
viral polymerase (Choi et al. 2018).
HBV is characterized by its high replication capacity 
(> 1012 virion/day) and a lack of proofreading activity 
during replication (10–5 substitution/base/cycle). This 
means that each nucleotide on the HBV genome can 
be changed within a day and cause antiviral resistance-
related mutations before treatment (Tezcan et al. 2015). 
Also, the S gene is completely overlapped by the pol 
gene. Because of this overlap between the S and the pol 
gene, changes that are related to antiviral resistance in 
the pol gene may also occur in the S gene as well (Sayan 
et al. 2012). This overlap leads to amino acids structure, 
found in surface antigen (HBsAg) of HBV to change 
and thus form naturally occurring antiviral resistance 
mutations. The vaccine escape, diagnosis escape, hepa-
titis  B immunoglobulin (HBIg) escape, and immune 
escape variants against oral antivirals that are used in 
chronic HBV treatment may emerge. Another reason 
for the emerging of these mutations is the occurrence 
of the mutant viruses deriving from antiviral-treated 
patients (Zhao et al. 2016). These changes cause reacti-
vation of HBV in vaccinated people and concerns dur-
ing diagnosis and/or HBIg vaccination failure (Wang 
et al. 2017; Asan et al. 2018).
Cyprus is an island located in the Mediterranean 
Sea and has been divided into two communities 
(Northern and Southern Cyprus). Northern Cyprus, 
officially the Turkish Republic of Northern Cyprus, 
is a multinational society due to universities, casinos, 
luxury hotels, beaches, and other entertainment cent-
ers; thus, there are many people coming from foreign 
countries for education, business and/or tourism pur-
poses. For HBV infection, the prevalence rate ranges 
from 1.2% (160/13 892) (Arikan et al. 2016) to 1.35% 
(339/25 442) (Guler et al. 2018). For Southern Cyprus, 
this rate was given as 0.77% and 1.01% (Altindis et al. 
2016). Although there are few studies regarding the 
prevalence, up to now, there has been no publication 
on drug resistance in patients infected with HBV in 
Northern Cyprus (Altindis et al. 2006; Suer et al. 2014). 
Therefore, we aimed to show the presence of resistance 
mutations and their clinical significance in untreated 
chronic hepatitis B patients in Northern Cyprus.
Experimental
Materials and Methods
In our study, the samples of 100 patients with 
HBsAg positive who had never been treated with NAs 
or IFN, were involved retrospectively. The study group 
consisted of 13 892 people who applied to the Near East 
University Microbiology Laboratory for assessment of 
hepatitis markers during three years. Of these individu-
als, 100 samples with positive HBsAg were included in 
the study for drug resistance analysis. The levels of viral 
markers [HBsAg, anti-hepatitis B core antigen (anti-
HBc), anti-hepatitis B e antigen (anti-HBe), hepatitis B 
e  antigen (HBeAg), alanine aminotransferase (ALT), 
and aspartate aminotransferase (AST)] were deter-
mined by using the chemiluminescent enzyme immu-
noassay kits according to the manufacturer instructions 
[(Architect i200, Abbott, USA), (Roche, Cobas E411), 
Table I
Demographic and clinical characteristics of the study group.
F – female, M – male, ALT – alanine aminotransferase, AST – aspartate 
aminotransferase, SD – standard deviation 
Patient, n  100
Gender, F/M, n (%)  13 (13%)/87 (87%)
Age, median year (range) 35 (18–65)
Nationality, region/country, n (%)
 Asia  68 (68)
 Turkey  43 (63)
 Northern Cyprus  14 (21)
 Pakistan  3 (4)
 China  3 (4)
 Turkmenistan  3 (4)
 Syria  1 (2)
 Georgia  1 (2)
 Africa  29 (29)
 Nigeria  28 (97)
 Benguela  1 (3)
 North America  1 (1)
 Mexican    1 (100)
 Europe  2 (3)
 Azerbaijan   1 (50)
 Bulgaria    1 (50)
Anti HBc IgG positivity, n (%) 96 (96)
HBeAg positivity, n (%) 5 (5)
ALT (average ± SD) (U/L) 23 ± 19
AST (average ± SD) (U/L) 28 ± 19
HBV DNA median IU/ml (range) 1.0 + E7
 (1.9 + E1 – 2.8 + E8)
Genotype/subgenotype of HBV, n (%)
Genotype D  53 (78.0)
     D1  48 (70.6)
     D2  4 (5.9)
     D3  1 (1.5)
Genotype A   7 (10.2)
     A1  5 (7.3)
     A2  2 (2.9)
Genotype E   8 (11.8)
Treatment status, n (%)
Naïve  100 (100%)
Under treatment    –
Variable Study Group
pol/S gene mutations3 319
(Olympus AU680, Beckmann Coulter IFCC)]. HBsAg 
positive sera were stored at –80°C until use. The ethical 
approval of the study was taken from Near East Univer-
sity Scientific Researches Evaluation Ethics Committee 
(YDUBADEK, 20/06/2013 date and NEU/2013/16-88 
decision number).
The viral loads of positive samples were determined 
by using real-time polymerase chain reaction (PCR) 
technique according to the manufacturer instructions 
(artus HBV QS RGQ Qiagen, Hilden, Germany). The 
HBV pol gene (RT region between 80.–250. aa) was 
sequenced (between 254.–995. nucleotides), ampli-
fied and analyzed for pol/S gene mutations (Sayan 
et al. 2010a). Hepatitis B virus DNA (HBV DNA) was 
extracted from positive serum samples (Anatolia Gene-
works, Bosphore® Viral DNA Extraction Spin Kit ve 
Magnesia® 16 Magnetic Bead Extraction System, Istan-
bul, Turkey). HBV polymerase region was amplified 
by using a pair of primers (forward: 5’-TCGTGGTG-
GACTTCTCTCAATT-3’and reverse: 5’-CGTTGACA-
GACTTTCCAATCAAT-3’) (Sayan et al. 2010a; 2010b). 
PCR conditions were 95°C for 10 min, followed by 
35 cycles consisting of 95°C for 45 s, 60°C for 45 s, and 
72°C for 45 s (Sayan et al. 2010a). High Pure PCR Prod-
uct Purification Kit (Roche Diagnostics GmbH, Man-
nheim, Germany) was used to purify all PCR products. 
The sequencing was performed on ABI PRISM 3130 
(Applied Biosystems Inc. Foster City, USA) platform by 
using Phire Hot Start DNA polymerase (FinnzymesOy) 
enzyme and BigDye Terminator v3.1 Cycle Sequenc-
ing Kit (Amersham Pharmacia Biotech Inc.), 36 cm 
capillary and POP-7 TM polymer (Applied Biosys-
tems Inc.). The obtained data were analyzed by using 
Geno2pheno Drug Resistance program (the Center of 
Advanced European Studies and Research, Bonn, Ger-
many) which searches for HBV drug resistance muta-
tions at amino acid positions 80., 84., 85., 91., 169., 173., 
180., 181., 184., 191., 194., 202., 204., 214., 215., 233., 
236.–238., and 250. in the RT domain of the polymerase 
(Shaw et al. 2006). At the same time, the overlapping 
S  gene segments at amino acid positions 121., 135., 
137., 139.–149., 151.–153., 155.–157., 161., 164., 172., 
173., 175., 176., 182., 193.–196. were also analyzed and 
monitored for HBsAg vaccine escape, diagnosis escape, 
HBIg escape, and immune escape mutations (Avellon 
and Echevarria 2006).
Results
The current study consisted of HBsAg positive-
treatment naïve 100 CHB patients, of whom 13 were 
female and 87 were male, whose ages varied between 
18–65 ages (with a median of 35 years). The origins 
of the patients were from Asia (68%), Africa (29%), 
North America (1%) and Europe (2%), and none of 
them have been taken antiviral therapy when their 
serum samples were collected. Ninety-six percent 
and 5% of the study group were positive for anti-HBc 
IgG and HBeAg, respectively. The serum HBV DNA 
level was calculated as a median of 1.0 + E7 (range: 
1.9 + E1 – 2.8 + E8). ALT and AST levels were reported 
as 23 ± 19 and 28 ± 19, respectively. We sequenced only 
the samples of 68 patients in this study because HBV 
DNA was determined below 1000 IU/ml in 32 (32%) 
patients’ samples. The distribution of genotypes of the 
sequenced patients (68/100) was determined as D1 
(n:48, 70.6%), D2 (n:4, 5.9%), D3 (n:1, 1.5%), A1(n:5, 
7.3%), A2 (n:2, 2.9%), and E (n:8, 11.8%) (Arikan et al. 
2016). Demographic and laboratory findings of the 
study are displayed in Table II.
In the pol region, there was no primary drug 
resistance mutation detected in this study. There was 
only one treatment-naïve patient (1.5%) who had the 
partial resistance mutation at rt173M amino acid 
substitution that may be related with LAM and LdT 
resistance. Twenty-five patients (36.7%) had secondary/
compensatory mutations and the mutations patterns 
(rtL91I, rtQ149K, rtQ215H/P/S and rtN238D) were 
depicted in Table II.
In the S region, 30 (44%) patients had typical HBsAg 
escape mutations. Vaccine escape, diagnosis escape, 
 Primary resistance mutation ND ND –
 Partial resistance mutation rtV173M LAM-LdT related  1 (1.5)
Pol gene  rtL91I LdT related
 Compensatory mutation rTQ149K ADV related 25 (36.8)  rtQ215H/P/S LAM-ADV related
  rtN238D LAM-ADV related
Table II
Mutation characteristics of the HBV pol/S gene mutation patterns to the nucleos(t)ide analogues
in treatment naïve HBV carriers.
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HBIg, immune escape mutations were determined in 
7/68 (10%), 3/68 (4%), 4/68 (6%), 16/68 (24%) sam-
ples of the patients, respectively and these mutations 
are presented in Table III.
There were also six different combined mutations. 
The mutation patterns were sI110L + sS193L, sP120L + 
+ sT123N + sT126I + sA128V + sY134H + sD144E + 
+ sG145A, sT118A + sP127T, sI110L + sP120T + sD144A+ 
+ sG145R and sP120R + sC121Y + sT131I + sS132P. The 
resistance mutation patterns are given in Table III.
Discussion
Even in treatment naïve patients because of the 
high replication capacity and the overlapping read-
ing frames, antiviral resistance mutations may occur 
throughout the HBV genome (Yano et al. 2015). To 
our knowledge, this is the first study that focused on 
the resistance mutations in the HBV pol and S gene 
regions in treatment naïve CHB patients in Northern 
Cyprus. This information has confirmed that there 
was no primary drug resistance mutation in untreated 
patients. So, even if patients undergo long-term therapy 
with NA, they may not require periodic monitoring for 
the primary drug resistance. The previous studies indi-
cated that primary resistance mutations could occur 
not only in patients undergoing an NA therapy but also 
might be detectable in patients receiving any treatment 
(Bottecchia et al. 2016; Zhao et al. 2016; Asan et al. 
2018). The mutations that occur mainly at the amino 
acid positions 181, 204, 233 and 236 have been shown to 
be related with the primary resistance mutations in the 
treatment naïve patients (Asan et al. 2018). However, 
the mutations at the amino acid positions rt184, rt194, 
rt202, rt250 are mainly classified as partial resistance 
mutations and often act as compensatory mutations. 
The main functions of primary and partial resistance 
mutations are to reduce drug susceptibility and restore 
the viral replication defects, respectively (Asan et al. 
2018). Thereof, the drug resistance should be analyzed 
during and/or before initiating the treatment to reduce 
the risk of liver damage and consequently progression 
of hepatocellular carcinoma. Sayan and his colleagues 
from Turkey have shown in many studies that acyclic 
phosphonate related mutations could occur in CHB 
patients (Sayan 2010b; Asan et al. 2018; Ozguler and 
Sayan 2018).  Similarly, resistance mutations have been 
identified from other studies conducted in China and 
Pakistan (Mahmood and Anwar 2017; Zhao et al. 2016) 
which supports that primary resistance mutations can 
occur all over the world.
In the current study, we detected rtV173M par-
tial resistance mutation in one patient according to 
Geno2pheno Drug Resistance Program, however, the 
rtV173L substitution has been reported more com-
monly in the literature (Lin et al. 2012; Gürsoy et al. 
2019). Both amino acid substitutions are regarded as 
compensatory mutations and enhance viral fitness 
(Asan et al. 2018). The single compensatory mutation 
profiles are generally associated with low-level resist-
ance; however, they may cause high-level resistance 
when they combine with other patterns (Lazarevic 
2014). Thus, screening to detect resistance may be 
 sY100C, sI110L, sP120L/R,
 sT123N, sT127L, sP127T,
Immune escape sA128V, sT131N, sS132P,  16 (24) Immune response -vaccine sI110L + sS193L 1 (1.5)
 sY134F/H, sT140I/S, sS143T,
 sD144E, sS144T, sP210S
    sP120L + sT123N
Vaccine escape sT126I, sD144A/E, sG145A/R,  7 (10) Vaccine-HBIg + sT126I + sA128V 1 (1.5) S193L, sP210T   + sY134H + sD144E
    + sG145A
HBIg* escape sT118A, sP120T, sD144A/E,  4 (6) Immune response -HBIg sT118A + sP127T 1 (1.5) sG145A/E/R 
   Immune response-vaccine-HBIg sI110L + sP120T 1 (1.5)
Diagnostic escape sT118A, sT131I, sP120T,  3 (4)  + sD144A + sG145R sC121Y, sD144A, sG145R  Immune response-diagnosis sP120R + sC121Y, 2 (3)
    sT131I + sS132P
Total  30 (44)   6 (9)
Table III
Typical HBsAg escape and combined mutations of the study patients (n = 68).
* HBIg – Hepatitis B immunoglobulin
** Patients may have more than one mutation pattern
Typical HBsAg
escape mutation Mutation patterns n (%) Combined mutations Mutation patterns n (%)
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regarded to be a benefit in the control of CHB. Sayan 
has shown in one of his studies that rtV173L muta-
tion combined with sD144E produced HBV vaccine 
escape + HBIG escape (Sayan and Bugdaci 2013). LAM-
associated resistance triple mutation pattern (rtV173L + 
rtL180M + rtM204V) has also been shown to enhance 
viral replication compared with rtL180M + rtM204V 
(Sheldon and Soriano 2008).
In the current study, among 68 patients, there 
were 25 (37%) secondary/compensatory resistance 
mutations (rtL91I, rtQ149K, rtQ215H/P/S, rtN238D) 
which are related to LdT, LAM, and ADV resistance 
(Saran et al. 2017; Asan et al. 2018). It may be a result 
of naturally emerging mutations due to the biology of 
HBV. The most common compensatory mutations have 
been reported to be rtQ149K, rtQ215H/P/S and rtL91I 
(Asan et al. 2018). These compensatory mutations are 
important as they assist viral replication and fitness, 
and hence are associated with drug resistance (Ahn 
2015). In our study, we determined one of the most 
commonly detectable compensatory mutation rtQ215/
H/P/S, which is associated with LAM and ADV resist-
ance (Shaw et al. 2006; Altindis 2016; Asan et al. 2018).
Mutations in the pol gene, due to the structure of 
HBV, also occur in the overlapping HBsAg (Zaaijer 
et al. 2007; Simon et al. 2013) and some typical HBsAg 
escape mutations emerge. The immune response 
escape, HBV vaccine escape, HBIg escape, and HBsAg 
diagnosis escape were detected in 44 patients in this 
study. sP120T, Sm133I, Ss143L, sD144A/E, sD145R and 
Se164D are the most frequently detected typical HBsAg 
escape mutations in CHB patients (Sayan et al. 2010b). 
Misdiagnosis in the HBsAg, failure to prevent with 
vaccination and HBIg, reactivation of hepatitis B, and 
re-infection in HBV infected recipients and/or ortho-
tropic liver transplantations may be a consequence 
of the typical escape mutations (Asan et al. 2018). All 
patients that receive or not receive antiviral treatment 
should be monitored for these mutations.
In conclusion, these findings on drug resistance 
mutations show that treatment-naïve CHB patients 
have low HBV polymerase resistance mutation (1.5%) 
rate. Hence, primary drug resistance analysis may not 
be necessary to be performed before the initiation 
of antintiviral therapy; however, we have discovered 
a novel compensatory mutation, rt173M that may act 
as a primary mutation together with other patterns. To 
draw attention, we preferred to define this mutation as 
a partial resistance mutation rather than compensatory 
resistance mutation in this study. Additionally, HBsAg 
escape mutants in patients living in Northern Cyprus 
demonstrated us that early detection of possible S gene 
mutations may be beneficial and important to moni-
tor the surveillance of S variants. Even though national 
compulsory HBV vaccination program, these mutants 
may develop in hepatitis B vaccinated and/or HBIG 
vaccinated individuals with CHB, in chronic carriers 
and/or patients undergoing antiviral treatment and may 
pose danger for public health. In addition, due to the 
arrival of people from many countries to North Cyprus 
for the reasons we have stated, drug resistance muta-
tions should be analyzed as pol and S gene together for 
monitoring CHB.
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